Hong Kong Laureate Forum: Calling Outstanding Young Scientists in Astronomy, Life Science and Medicine, and Mathematical Sciences!
14.9.2020 04:00:00 EEST | Business Wire | Press release
Open application for the inaugural Hong Kong Laureate Forum starts today and will end on 13 December 2020. We welcome undergraduates, postgraduates and PhD graduates who are aged 35 or below and studying or conducting research in Astronomy, Life Science and Medicine, Mathematical Sciences or other closely related subjects to apply for the Hong Kong Laureate Forum and become one of the 200 selected young scientists to be inspired by world-renowned Shaw Laureates. Eligible Young Scientists are welcome to complete and submit their applications via this link: https://hklaureateforum.org/en/application-form
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200913005003/en/
Open Application from 14 September to 13 December 2020 (Graphic: Business Wire)
The inaugural Hong Kong Laureate Forum will be held on 15-20 November 2021 in Hong Kong. Being Asia’s world city and a city long celebrated for its vibrancy, Hong Kong is an ideal place for such an international gathering.
During a week-long programme, there will be ample opportunities for exchanges between participating Shaw Laureates and the young scientists. Apart from plenary lectures, panel discussions and parallel group sessions conducted by Shaw Laureates and other distinguished scientists, the programme will also offer informal and cozy gatherings with plenty of chances of networking and dialogues. There will also be presentation sessions for selected young scientists to showcase their latest research ideas to spark intellectual exchanges.
Mrs DO PANG Wai Yee, Secretary-General of the Council of the Hong Kong Laureate Forum (the HKLF) said: “As of today, we have received positive response from over 20 Shaw Laureates, including several Nobel Laureates and Fields Medalist, to join our Forum.”
Professor Steven Balbus, Shaw Laureate in Astronomy 2013 remarked: “I have nothing but pleasant memories of Hong Kong and I look forward to many more. It’s a city that feels exciting and that things are working. I think the Hong Kong Laureate Forum is going to be extremely exciting and a very special program that’s going to capture the imagination of the public.”
Professor Simon White, Shaw Laureate in Astronomy 2017 said: “I think the significance of the Shaw Prize is because it makes certain aspects of science visible to a wider public. And this fuels the curiosity which leads people to do science, which pushes them to improve their capabilities. I hope the Hong Kong Laureate Forum will make young people really enthusiastic and curious about science.”
The most outstanding 200 young scientists will be selected to join the inaugural Forum by a Scientific Review Panel comprising local and non-local academics. All applicants, either successful or not, will receive email notification in April 2021.
For enquiries regarding application, please contact Forum Programmes and Participants Enquiry at programme@hklaureateforum.org.
Background
The Hong Kong Laureate Forum is an annual scientific exchange event organized by the HKLF. It aspires to be a world-class academic exchange event to connect the current and next generations of leaders in scientific pursuit. The Forum also promotes understanding and interests of the young generation in Hong Kong and around the world in various disciplines in science and technology. The HKLF was launched in May 2019 and is fully sponsored by Lee Shau Kee Foundation. The important partner of the HKLF is The Shaw Prize Foundation which organizes the annual international award The Shaw Prize.
To the Press
With this press release, we would like to extend an invitation to the Press to attend and report on the inaugural Hong Kong Laureate Forum.
Website:
https://www.hklaureateforum.org
Facebook:
https://www.facebook.com/HKLaureateForum
Twitter:
https://www.twitter.com/HKLaureateForum
Weibo:
https://www.weibo.com/hklaureateforum
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200913005003/en/
Contact information
Forum Programmes and Participants Enquiry
Koji Ho
programme@hklaureateforum.org
Tel: (852) 2905 6505
Media Enquiry
Kelvin Chau
media@hklaureateforum.org
Tel: (852) 2905 6506
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom